Disease · MONDO_0006781
Comparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 50
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Test Group vs Control Group: Safety by Assessment of the Number of Participants With Adverse Events (AEs) | 131 of 351 | 184 of 346 | 697 | NCT05857163 | Trial comparisons |
| Test Group vs Control Group: Eradication Rate of H.Pylori Infection | 323 of 351 | 304 of 346 | 697 | NCT05857163 | Trial comparisons |
| Test Group vs Control Group: deaths from any cause | 0 of 351 | 0 of 346 | 697 | NCT05857163 | Trial comparisons |
| Test Group vs Control Group: serious adverse events | 2 of 351 | 2 of 346 | 697 | NCT05857163 | Trial comparisons |
| TAK-438 20 mg vs Lansoprazole 30 mg: deaths from any cause | 0 of 263 | 0 of 268 | 531 | NCT03050359 | Trial comparisons |
| TAK-438 20 mg vs Lansoprazole 30 mg: serious adverse events | 1 of 263 | 3 of 268 | 531 | NCT03050359 | Trial comparisons |
| Vonoprazan 20 mg vs Esomeprazole 20 mg: deaths from any cause | 0 of 256 | 0 of 254 | 510 | NCT04198363 | Trial comparisons |
| Vonoprazan 20 mg vs Esomeprazole 20 mg: serious adverse events | 3 of 256 | 5 of 254 | 510 | NCT04198363 | Trial comparisons |
| RHB-105 vs Active Comparator: Number of Participants With Eradication of H. Pylori | 191 of 228 | 131 of 227 | 455 | NCT03198507 | Trial comparisons |
| RHB-105 vs Active Comparator: deaths from any cause | 0 of 228 | 0 of 227 | 455 | NCT03198507 | Trial comparisons |
| RHB-105 vs Active Comparator: serious adverse events | 1 of 228 | 1 of 227 | 455 | NCT03198507 | Trial comparisons |
| Reverse Hybrid Therapy vs Standard Triple Therapy: Number of Participants in Which H. Pylori Was Eradicated | 206 of 220 | 191 of 220 | 440 | NCT02359435 | Trial comparisons |
| Reverse Hybrid Therapy vs Standard Triple Therapy: serious adverse events | 0 of 220 | 0 of 220 | 440 | NCT02359435 | Trial comparisons |
| Quadruple Therapy (OBMT) 10 Days vs Triple Therapy (OAC) 7 Days: Number of Patients Experiencing Treatment Emergent Adverse Events. | 101 of 216 | 112 of 222 | 438 | NCT00669955 | Trial comparisons |
| Quadruple Therapy (OBMT) 10 Days vs Triple Therapy (OAC) 7 Days: serious adverse events | 4 of 216 | 3 of 222 | 438 | NCT00669955 | Trial comparisons |
| RHB-105 vs Active Comparator: Number of Participants With Eradication of H. Pylori in the Pharmacokinetic Population (PKP) | 187 of 207 | 119 of 184 | 391 | NCT03198507 | Trial comparisons |
| Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants With Adverse Event | 93 of 195 | 72 of 195 | 390 | NCT02159976 | Trial comparisons |
| Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants With Successful H. Pylori Eradication | 146 of 195 | 134 of 195 | 390 | NCT02159976 | Trial comparisons |
| Sequential Therapy vs Modified Bismuth Quadruple Therapy: serious adverse events | 0 of 195 | 0 of 195 | 390 | NCT02159976 | Trial comparisons |
| Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants Whose Drug Compliance is More Than 85% | 165 of 176 | 170 of 177 | 353 | NCT02159976 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006781/comparisons